                               SEQUENCE LISTING

<110> DICERNA PHARMACEUTICALS, INC.
 
<120> REDUCING BETA-CATENIN EXPRESSION TO POTENTIATE IMMUNOTHERAPY

<130> 0243.0007-PCT

<140>
<141>

<150> 62/477,783
<151> 2017-03-28

<160> 3     

<170> PatentIn version 3.5

<210> 1
<211> 26
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 1
agaauacaaa ugauguagaa acagcc                                            26


<210> 2
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<220>
<223> Description of Combined DNA/RNA Molecule: Synthetic
      oligonucleotide

<400> 2
uagcuaucgt ggcuguuucu acaucauuug uauucugc                               38


<210> 3
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 3
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


